Global Glaucoma
Eye Drops Market, by Drug Type (Prostaglandin analogs, Beta blockers, Alpha
agonists, Carbonic Anhydrase Inhibitors (CAIs), Combined Medications and Others
(rho-kinase inhibitor, Cholinergic agonist)), by Disease Indication
(Angle-closure Glaucoma and Open-angle Glaucoma), By Distribution Channel
(Hospital Pharmacy Retail Pharmacy and Online Pharmacy), by Composition
(Preservative Free, BAK-Based and Non BAK-Based Preservatives ), and by Region
(North America, Latin America, Europe, Asia Pacific, Middle East, and Africa),
is estimated to be valued at US$ 1,360.1 million in 2020 and is expected to
exhibit a CAGR of 7.0% during the forecast period (2020-2027), as highlighted
in a new report published by Coherent Market Insights.
Key players in the market have a
number of drugs undergoing clinical trials for treatment of glaucoma and are
expected to receive approval in the near future. The robust pipeline of
glaucoma medications is expected to drive growth of global glaucoma eye drops
market in the near future. For instance, in January 2019, Santen Pharmaceutical
Co., Ltd. started a clinical trial on drug candidate DE-111A (that is a
preservative-free, clear, colorless sterile aqueous ophthalmic solution
containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL) for the treatment
of open-angle glaucoma, and ocular hypertension. The clinical trial included
324 patients. This clinical trial is in phase 3 and is expected to complete by
the end of June 2020.
Similarly, Zhaoke (Guangzhou)
Ophthalmology Pharmaceutical Ltd., China in November 2015, initiated a clinical
trial with Levobetaxolol eye drops for treatment of primary open-angle glaucoma
and ocular hypertension.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/3984
This study is to evaluate the
safety and efficacy of Levobetaxolol in Chinese patients with glaucoma. This
study included 366 Chinese patients with glaucoma. The clinical trial is in
phase 3 and is expected to be completed by December 2021.
There have been several
developments in glaucoma medications in the recent past. Therefore, robust
pipeline for treatment of glaucoma is expected to boost the glaucoma eye drops
market growth in the near future.
Browse 25 Market Data Tables and
28 Figures spread through 144 Pages and in-depth TOC on Glaucoma Eye Drops
Market, by Drug Type (Prostaglandin analogs, Beta blockers, Alpha agonists,
Carbonic Anhydrase Inhibitors (CAIs), Combined Medications and Others
(rho-kinase inhibitor, Cholinergic agonist)), by Disease Indication
(Angle-closure Glaucoma and Open-angle Glaucoma), By Distribution Channel
(Hospital Pharmacy Retail Pharmacy and Online Pharmacy), by Composition
(Preservative Free, BAK-Based and Non BAK-Based Preservatives ), and by Region
(North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)-
Forecast to 2027"
Key Takeaways of the Glaucoma Eye
Drops Market:
The global glaucoma eye drops
market is expected to exhibit a CAGR of 7.0% during the forecast period
(2020-2027) owing to the robust product pipeline for treatment of glaucoma.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/glaucoma-eye-drops-market-3984
Among drug type, the consumables
segment is expected to hold a major revenue share in 2027 owing to product
approvals by regulatory bodies. For instance, in November 2017, Bausch Health,
a global eye health company, and Nicox S.A., an international ophthalmic
company, announced that the U.S. Food and Drug Administration (FDA) approved
the New Drug Application (NDA) for VYZULTA (latanoprostene bunod ophthalmic
solution, 0.024%) for glaucoma.
Major players operating in the
global glaucoma eye drops market are Merck & Co., Inc., Allergan Plc.
Novartis AG. Teva Pharmaceutical Industry, Pfizer, Inc., Bausch & Lomb
Inc., Inotek Pharmaceutical, Jadran-galenski laboratorij d.d., Aerie
Pharmaceutical, and Mylan N.V.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/3984
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment